AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Q1 2008 MannKind Earnings Conference Call - Final.
Original Source: FD (FAIR DISCLOSURE) WIRE
OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to the MannKind Corporation first quarter 2008 conference call. At this time, all participants are in a listen-only mode. Later instructions will be given for the question-and-answer session. (OPERATOR INSTRUCTIONS) As a reminder, this call is being recorded today, May 5, 2008. Joining us today from MannKind are Chairman and CEO, Alfred Mann, President and COO, Hakan Edstrom, the Chief Financial Officer, Matthew Pfeffer, and Chief Scientific Officer, Peter Richardson.
I would now like to turn the call over to Mr. Matthew Pfeffer, Chief Financial Officer of MannKind Corporation. Please go ahead.
HAKAN EDSTROM, PRESIDENT, COO, MANNKIND: This is Hakan Edstrom. Good afternoon, and thank you for participating in today's call. Before we proceed further, please note that comments made during this call will include forward-looking statements within the meaning of Federal Securities laws. It is possible that the actual results could differ from these expectations, and for factors that could cause actual results to differ from expectations. Please refer to reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934.
Let me start by recapping our activities during the past quarter. All of our key programs are on-schedule, and are on and below budget. We are nearing the end of our pivotal Phase III trials and put in place the necessary personnel and systems, so that we can lock the databases this fall, and conduct the analysis leading to the NDA filing. We are also approaching the completion of construction phase of our manufacturing facility in Danbury.
- MannKind makes $175M placing.(Technosphere Insulin System development)(Brief...
- Newspaper article from: Pharma Marketletter August 8, 2005 700+ words
...proceeds from the financing primarily to fund the continuing development program for the Technosphere Insulin System, which is currently in Phase III clinical trials in the USA and Europe. They are also expected to be used for the company...
- Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low...
- Press release article from: PR Newswire April 19, 2006 700+ words
...patients with Type 1 diabetes using Technosphere Insulin can achieve comparable levels of...controlling mealtime blood sugar spikes. Technosphere Insulin has a more rapid onset of action...test were lower for patients on Technosphere Insulin than those receiving injections...
- MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere...
- Press release article from: PR Newswire September 16, 2008 700+ words
...efficacy of prandial inhalations of Technosphere Insulin (the TI group) versus prandial...insulin glargine). Study Highlights Technosphere Insulin, compared to a rapid-acting insulin...effects on fasting glucose levels. Technosphere Insulin promises to be an important additional...
- Technosphere/Insulin therapy properties presented at international meeting.
- Newspaper article from: Drug Week October 8, 2004 700+ words
...delivery and glucose control with its Technosphere/Insulin system that are not available from...diabetologist, described the ability of Technosphere/Insulin to produce a rapid increase in blood...blood stream. In addition, the Technosphere/Insulin system was shown to have an effect...
- MannKind Provides Update on Technosphere Insulin System.
- Press release article from: PR Newswire November 10, 2004 700+ words
MannKind Corporation today announced at the CIBC World Markets Fifteenth Annual Healthcare Conference that it recently held an "End of Phase 2" meeting with U.S. Food and Drug Administration (FDA) officials to discuss the Company's Technosphere(R) Insulin System, which is under development to
- Alkermes Starts Phase III Of Inhaled Insulin Product.
- Magazine article from: BIOWORLD Today November 3, 2009 700+ words
...has started an additional Phase III registrational study in...insulin. Alkermes began its Phase III pivotal program last July...inhaled insulin product, Technosphere Insulin. The company started two Phase III studies in March, and...
- MannKind's Inhaled Insulin In Phase III Efficacy Studies.
- Magazine article from: BIOWORLD Today Lorenzo, Aaron March 7, 2006 700+ words
...inhaled insulin product, Technosphere Insulin (TI), with two additional Phase III studies now started...two recently completed Phase III trials, a three-month...forward. A fifth and final Phase III trial, Study 103, is...
- MANNKIND RAISES $175M TO DEVELOP INHALED INSULIN SYSTEM.
- Magazine article from: BIOWORLD Today Lorenzo, Aaron August 4, 2005 700+ words
...further developing its Technosphere Insulin System, which already is in Phase III testing. A U.S...safety of inhaled Technosphere Insulin, while an efficacy...significantly improved when Technosphere Insulin was added to oral...